Zimbabwe has declined a significant American healthcare agreement worth $367m (272 million pounds) over five years over Washington's demand for sensitive biological samples.
The decision was revealed after a internal memorandum dated December was disclosed, revealing that Head of State Emmerson Mnangagwa believed the deal was "skewed".
A government spokesperson later explained that the US was seeking biological samples for scientific study and commercial purposes but refused to share the resulting advantages from any future medical innovations.
"We are forced to start the difficult and regrettable process of winding down our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had donated over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has urged continued talks to find a deal agreeable to both sides so the nation's vital HIV treatment initiative can be sustained.
Broader Background
This development comes after a similar case in neighbouring Kenya, where a court suspended a similar deal with the US after legal challenges were filed about the security of Kenyans' medical information.
After returning to office recently, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had managed assistance for the American government, but Trump claimed its spending was "wasteful" and his administration was seeking direct bilateral agreements to enhance openness and responsibility.
Based on reports, Sixteen African countries have to date signed these new health pacts, representing more than $18.3bn in committed funds.
Specifics of the Rejected Agreement
The money for Zimbabwe was intended to funded "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this collaboration might have yielded immense benefits for Zimbabwean communities, particularly the 1.2 million presently on HIV treatment via US-supported initiatives," Tremont commented.
However, government spokesperson Nick Mangwana argued the arrangement was "asymmetrical".
"The proposal required Zimbabwe to share its genetic material and health information over an extended period, with no equivalent guarantee of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could result from that provided information," Mangwana explained.
"Effectively, our country would provide the basic resources for medical research without any assurance that the final treatments would be available to our citizens should a new pandemic emerge."
National Interest and Global Health
Mangwana further said that the American exit from the global health body and its push of one-on-one health agreements were disrupting structures already established via the international health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing system created to deal with potential pandemics.
"This system is designed to guarantee that when a nation contributes its information, the resulting advantages – such as vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the capability to develop them."
These objections over the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We welcome further discussions with our US partners on how subsequent collaboration might be structured in a manner that honours the sovereignty and interests of both nations."
Medical Community Reaction
A leading public health body said it recognised the official position, but recommended that negotiations must proceed since much of the nation's HIV programmes relied on foreign aid.
"If specific concerns arise, such as those relating to data governance or agreement terms, these can often be resolved through technical clarification and negotiated safeguards," it added.
The halted deal underscores the ongoing debate between accepting vital international aid and safeguarding national sovereignty in an increasingly data-driven world.